Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Quiz|Articles|October 18, 2026 (Updated: September 23, 2026)
NeurologyLive® Brain Games: October 18, 2026
Author(s)Louie Pasculli
Listen
0:00 / 0:00
Key Takeaways
- Weekly publication cadence is Sunday morning, with content written by physicians, clinicians, and neurological care and advocacy experts.
- Questions span major neurology domains, including dementia/Alzheimer disease, epilepsy, headache, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and stroke.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of biomarkers in multiple sclerosis!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
A 34-year-old patient with relapsing-remitting multiple sclerosis (RRMS) is clinically stable on a disease-modifying therapy. Routine MRI shows no new lesions, but serum neurofilament light chain (sNfL) has increased substantially from the patient's prior baseline. Which interpretation is most appropriate?
A clinician is considering serum glial fibrillary acidic protein (sGFAP) and sNfL to help characterize disease activity in a patient with progressive MS. Which statement best describes the biological distinction between these biomarkers?
A patient undergoing evaluation for possible MS has a lumbar puncture. The cerebrospinal fluid (CSF) demonstrates evidence of intrathecal immunoglobulin synthesis. Which finding is most directly used to demonstrate this process in routine MS diagnostic workups?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
2
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
3
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5